Corporate Info
Smart Quotes
Company Background
Board of Directors
Balance Sheet
Profit & Loss
Peer Comparison
Cash Flow
Shareholdings Pattern
Quarterly Results
Share Price
Deliverable Volume
Historical Volume
MF Holdings
Financial Ratios
Directors Report
Price Charts
Notes Of Account
Management Discussion
Beta Analysis
Board Meetings
Corporate Announcements
Book Closure
Record Date
Bonus
Company News
Bulk Deals
Block Deals
Monthly High/low
Dividend Details
Bulk Deals
Insider Trading
Advanced Chart
HOME   >  CORPORATE INFO >  BOARD MEETINGS
Board Meetings      
Gufic Biosciences Ltd.
Source DateBoard Meeting DateDetails
07-Aug-2025 13-Aug-2025 Quarterly Results
23-May-2025 30-May-2025 Audited Results & Final Dividend
07-Feb-2025 14-Feb-2025 Quarterly Results
08-Nov-2024 14-Nov-2024 Quarterly Results
08-Aug-2024 14-Aug-2024 Quarterly Results
23-May-2024 29-May-2024 Final Dividend & Audited Results
07-Feb-2024 14-Feb-2024 Quarterly Results
02-Nov-2023 09-Nov-2023 Quarterly Results
29-Aug-2023 01-Sep-2023 Preferential Issue of shares
04-Aug-2023 11-Aug-2023 Employees Stock Option Plan & Quarterly Results
23-May-2023 29-May-2023 Final Dividend & Audited Results
02-Feb-2023 10-Feb-2023 Quarterly Results
03-Nov-2022 11-Nov-2022 Quarterly Results
04-Aug-2022 11-Aug-2022 Quarterly Results
13-May-2022 20-May-2022 Final Dividend & Audited Results
02-Feb-2022 09-Feb-2022 Quarterly Results
27-Oct-2021 03-Nov-2021 Quarterly Results
04-Aug-2021 11-Aug-2021 Quarterly Results
28-May-2021 04-Jun-2021 Audited Results & Final Dividend Inter alia, to consider and approve 1. Allotment of 1,91,14,506 Equity Shares of Re. 1/-each to the shareholders of Gufic Lifesciences Private Limited (Transferor Company) pursuant to the order passed by Hon’ble National Company Law Tribunal (NCLT) Ahmedabad bench dated December 31, 2020 and NCLT Mumbai bench dated March 11, 2021, sanctioning the Scheme of Amalgamation of the Transferor Company with Gufic Biosciences Limited and their respective shareholders and creditors.
02-Feb-2021 08-Feb-2021 Quarterly Results
Page 1 of 7
Prev || Next
Disclaimer | Privacy Policy | Grievance | FAQ | Sitemap | Client Registration | Useful Links| Anti Money Laundering | Inactive Client Policy | Scores
Vernacular Kyc | Advisory For Investors | Investor Adviser | Filing complaints on SCORES - Easy & quick | Policy on PMLA | Publishing of investor charter information | Annexure A – Investor charter of brokers | Annexure A – Investor charter of DP | Annexure B –Linked content for information to charter for DP | Annexure B & C (investor complaint data) broker & DP | Investor Charter & Complaints | Advisory-KYC Compliance | E-Voting NSE | E-Voting BSE | Details of Client Bank Accounts | Risk Disclosure | NSE FO Risk disclosure | Details of Research Analyst
SEBI Regn. No.: INB010997431 (BSE), INB230997430 (NSE)
Copyright 2008 Javeri Fiscal Services Ltd.
Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.
CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Source: Click Here.